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the £20,000 and £30,000 willingness-to-pay thresholds for both treatment-naïve
patients and treatment-experienced patients regardless of IL-28B subtypes.
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EMTRICITABINA (FTC) EFAVIRENZ (EFV) IN HIV-INFECTED NAÏVE PATIENTS
IN MEXICO
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OBJECTIVES: Develop an economic evaluation of regimes Tenofovir/Emtricitabina
(Truvada
®
)EFV versus TDFFTCLPV/r, ABC3TCEFV, ABC3TCLPV/r,
ZDV3TCEFV in naïve patients infected with HIV through a cost-effectiveness
study from the public health system Mexican perspective. METHODS: We devel-
oped an economic Markov model to compare information on the effectiveness,
utility and costs of the use of Tenofovir/Emtricitabina (Truvada
®
)EFV versus
TDFFTCLPV/r, ABC3TCEFV, ABC3TCLPV/r, ZDV3TCEFV over a 2 year
period with six-month cicles. Efficacy was measured by the percentage of individ-
uals with plasmaHIV RNA 50 copies/mL and Qalys, based on a systematic review
and meta-analysis of clinical trial of regimens in treatment-naïve populations.
Model follows the recommendations of antiretroviral persons handling Guide with
HIV in Mexico (2010 SSA). The direct costs, treatment of adverse events, cost of
failure of the treatment and costs of medical attention of HIV were estimated and
were obtained from the mexican public health institutions. All costs were calcu-
lated in 2011 mexican pesos (MXP). Incremental cost effectiveness ratios were
expressed as cost per 1% of individuals with plama HIV RNA50 copies/ML and
Qalys. Costs and outcomes were discounted at 5%. Probabilistic sensitivity analy-
ses viaMonte Carlo simulations and a budget impact analysis (BIA) were perfomed.
RESULTS:Tenofovir/Emtricitabina (Truvada
®
)EFVwasmost effective than others
comparators with a probability of 0.562 HIV RNA 50 copies/mL and 1.614 Qalys.
Tenofovir/Emtricitabina (Truvada
®
)EFV resulted as the alternative with less av-
erage total cost per patients ($91,439.77). Tenofovir/Emtricitabina (Truvada®)EFV
is a dominant option and cost saving compared to the alternatives. Deterministic
probabilistic sensitivity analysis showed that the findings are robust. The analysis
of BIA show that public health system mexican could save about $140,480,959 if
they use Tenofovir/Emtricitabina (Truvada®)EFV rather than other options in
these patients. CONCLUSIONS: Tenofovir/Emtricitabina (Truvada®)EFV is an ef-
ficient and cost-saving drug on 96 weeks for the treatment of adult naïve patients
with HIV infection in Mexico.
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OBJECTIVES:What happens when technologies leave Randomized Controlled Tri-
als and approach the real world? Sometimes no answers are provided to this ques-
tion. The aim of the COALA study was to evaluate, taking the Italian NHS (payer)
perspective, the lifetime cost-utility of lopinavir/ritonavir vs. atazanavir  ritona-
vir, with a tenofovir-emtricitabine backbone, in a sample of 319 naïve patients
starting from, and developing, the assumptions of the Broder (2011) Markovmicro-
simulationmodel.METHODS: The health andmonetary outcomes associated with
ATVr and LPV/r regimens, were analyzed considering: 8 health states, incidence
of diarrhea and/or hyperbilirubinemia, AIDS events, opportunistic infections, and
CHD events and, for the first time in an economic evaluation concerning HIV
patients, CKD. Patients were enrolled in one of two scenarios: LPV/r or ATVr
(ATV1), and followed first or second line treatment. The two lines were both mod-
elled at an individual patient level. A sensitivity analysis regarding ATVr arm
(ATV2) was assessed, in order to replicate the results of the CASTLE trial study, and
to compare them with an ATV1 arm. The total cost per patient was calculated
considering drugs costs, clinical effectiveness data, as well as institutional guide-
lines, protocols and the Lombardy Region reimbursement tariffs. RESULTS: LPV
was assessedwith a gain in terms ofQALY equal to 0.150 to 0.447. Themodel results
show a higher incidence of cardiovascular events (6.5 per 1,000 inhabitants) for the
LPV arm, and a lower incidence of CKD (27.1 vs. 110.9-135.3) for LPV.
CONCLUSIONS: Considering the economic performance, there was an annual eco-
nomic per capita advantage between €73 and €138. This, in terms of QALY and
reduction of costs, reveals that LPV/r treatment gives a higher economical perfor-
mance and is more cost-effective compared with ATVr.
INFECTION – Patient-Reported Outcomes & Patient Preference Studies
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OBJECTIVES: Poor adherence to HIV antiretroviral therapies (ART) increases the
risk of incomplete viral suppression, development of viral resistance, progression
to acquired immune deficiency syndrome, and death. However, there is little un-
derstanding of the impact of specific treatment-related adverse events (AEs) on
adherence. This meta-analysis was conducted to assess the effects of treatment-
related AEs on adherence to ART in adult HIV-infected patients. METHODS: A
systematic review of studies involving HIV-infected patients aged 16 years and
reporting an odds ratio (OR) for factors affecting adherence to ART was conducted.
Embase and MEDLINE databases were searched between 1996 and 2010. Bibliogra-
phies of identified review papers were also searched. Studies conducted in popu-
lations limited to a particular demographic characteristic or behavioral risk factor
were excluded. To qualify for inclusion into the meta-analysis, treatment-related
AEs had to be defined similarly across studies. Multiple ORs from the same study
were included where study sub-groups were distinct. Random effects models were
used to pool ORs. RESULTS: Nineteen studies and 18 ART-related AEs were in-
cluded in the analysis. Adherence to ART was significantly lower in patients with
non-specific AEs than in patientswho did not experience anyAEs (OR0.62; 95%CI:
0.46-0.83). Patients with specific AEs such as cough (OR0.65; 0.53-0.79), fatigue
(OR0.63; 0.43-0.92), confusion (OR0.35; 0.18-0.66), anxiety (OR0.63; 0.41-0.95),
taste disturbances (OR0.49; 0.30-0.77), nausea (OR0.57; 0.43-0.77), and loss of
appetite (OR0.54; 0.32-0.93) were significantly less likely to adhere to ART com-
pared to patients without these AEs. Diarrhea, insomnia, sexual dysfunction, lip-
odystrophy, numbness, pain when swallowing, tingling in mouth/tongue, derma-
tological conditions, abdominal pain, and vomiting were not significantly
associated with adherence, although trends toward decreased adherence were
observed. CONCLUSIONS: Specific treatment-related AEs can significantly de-
crease adherence to ART. Knowledge of these effects may allow for targeted man-
agement of AEs to improve ART adherence and clinical outcomes.
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OBJECTIVES: The standard of care for hepatitis C (ribavirin and peginterferon) has
been found to be associated with an increased risk of anemia. The objective of this
study was to investigate the effect anemia has on health status and work produc-
tivity among patients currently treated for hepatitis C. METHODS: Data from the
2011 U.S. National Health and Wellness Surveys were used. Among respondents
who were currently or had formerly been treated for hepatitis C, those with and
without a diagnosis of anemia were compared on health status (using the SF-12v2)
andwork productivity (using theWPAI questionnaire) using general linearmodels.
Demographics, health behaviors, and comorbidities were also measured and in-
cluded as covariates. RESULTS: A total of 305 patients were currently or formerly
treated for hepatitis C. Of these patients, 22 reported having been diagnosed with
anemia (7.21%). The presence of anemia was associated with significantly lower
mental component summary scores (Mean37.00 vs. Mean45.21) and worse
health utilities (Mean0.53 vs. Mean0.67) (all ps.05). Impairment in daily activ-
ities was significantly higher among those with anemia (Mean65.00% vs.
Mean39.33%, p.05). Fewpatientswere currently employed (n7with anemia vs.
n121 without anemia), however, absenteeism (Mean34.00% vs. Mean5.79%),
presenteeism (Mean51.43% vs. Mean23.67%), and overall work impairment
(Mean61.00% vs. 25.98%) were all significantly higher among those with anemia
(all ps.05). The health status and activity impairment differences remained after
controlling for age, gender, ethnicity, smoking and theCharlson comorbidity index.
CONCLUSIONS: These results suggest that presence of anemia is associated with a
substantial humanistic and indirect cost burden among patients who are treated
for hepatitis C. Novel treatments which reduce the rate of anemia may result in a
substantial improvement in patient outcomes.
PIN47
THE HUMANISTIC AND ECONOMIC BURDEN OF HEPATITIS C ACROSS THE
UNITED STATES, EUROPE, AND ASIA
DiBonaventura MD1, Yuan Y2, Lescrauwaet B3, L’Italien G4, Liu GG5, Kamae I6,
Mauskopf JA7
1Kantar Health, New York, NY, USA, 2Bristol-Myers Squibb Company, Plainsboro, NJ, USA,
3Xintera Consulting BVBA, Leuven, Belgium, 4Bristol-Myers Squibb Company, Princeton, NJ,
USA, 5Peking University, Beijing, China, 6Keio University Graduate School of Health
Management, Fujisawa, Japan, 7RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: Although prior studies have examined the burden of hepatitis C
(HCV) within individual countries, no study has compared the burden across coun-
tries using a consistent methodology. The aim of this study was to quantify the
burden of HCV in the United States (US), France, Germany, Italy, Spain, the UK,
China, and Japan.METHODS: The 2010 5EU (N57,805), 2009 US (N75,000), 2008/
2009 Japan (N37,683), and 2009/2010 urban China (N33,261) waves of the Na-
tional Health andWellness Survey were used as data source. Within each country,
patients with a self-reported diagnosis of HCV were compared with those who did
not report a diagnosis of HCV on sociodemographics, health behaviors, comorbidi-
ties, and health outcomes (health status using the SF-12v2,work productivity using
the WPAI, and healthcare resource use in the past six months). The effect of HCV
was examined using regression analysis applying samplingweights. RESULTS:The
prevalence of HCV ranged from 0.26% (China) to 1.42% (Italy). Patients in Japan and
Italy (61.60 and 61.02 years, respectively) were the oldest, while patients in the US
were the most likely to be obese (39.31%) and have concomitant anxiety (38.43%)
and depression (46.05%) compared with other countries. Pooling countries and
adjusting for sociodemographics, health behaviors, and comorbidities, HCV was
associated with significantly lower physical component summary scores (b-2.51)
and health utilities (b-0.04) and greater overall work impairment (b8.79), physi-
cian visits (b2.91), and emergency department visits (b0.30) (all ps.05). The
effects on health status were strongest in the US and UK while the effects on
healthcare resource use were strongest in Japan. CONCLUSIONS: HCV was associ-
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ated with a significant humanistic and economic burden. These results suggest
that the manifestation of the HCV burden, and the profile of the patients them-
selves, varied dramatically by country. Successful disease management should be
cognizant of region-specific unmet needs.
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OBJECTIVES:Todescribe the sex and sex communication experiences of females in
second cycle institutions METHODS: A cross sectional study involving the use of
structured questionnaire and interview guidewas conductedwith female students
in two selected secondary-level institutions in Bekwai, Ghana. Data was collected
from 391 randomly selected and consented female adolescent students aged 18
years or less in 2011. Data was analysed into descriptive statistics with statistical
significance set at 0.05 or less and at 95% confidence interval RESULTS: The study
revealed that 202/391(51.7) respondents had ever had sex, 134/202(66%) were cur-
rently having sex. Of 202 who had ever had sex, 151/202 (74.8%) discussed sex with
their friends while 96/189(50.8%) who had never had sex also discussed sex with
their friends. The top threemajor sources of sexual informationwas obtained from
friends, 187/391(47.8%), parents 85/391(21.7%) and teachers, 70/391(17.9%). A ma-
jority, 55.5%, as compared to 41.9% of the respondents, disagreed that parents talk
freely about sex. There were statistically significant associations between sex dis-
cussant and ever had sex (chi square  271; p0.01) and source of information on
sex and ever had sex (chi square  21.7; p  0.01). CONCLUSIONS: A majority of
female adolescent students are sexually active. Parents of female adolescents are
unpopular sources of information about sex and hardly do they discuss sexual
issues with adolescents. Understanding factors influencing parents’ willingness in
discussing sexual issues about sex could be helpful inminimizing sex related prob-
lems among female adolescent students.
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OBJECTIVES: Patients’ living with HIV/AIDS perceptions of their position in life in
the context of the culture and value systems in which they live and in relation to
their goals, expectations, standards and concerns were assessed using the HAT-
QOL. We explored the impact of socio-demographic profile on the quality of life
domains.METHODS: Consenting outpatients who met criteria were consecutively
selected. Socio-demographic characteristics of the patients were profiled. Health
related quality of life was determined in the domains of Overall function, Life
satisfaction, Health worries, Financial worries, Medication worries, HIV mastery,
Disclosure worries, Provider trust, and Sexual function. Quality of life scores were
computed on the standard scale of 0 - 100 and triangulated with a rated interval
scale of 1-5 suited for quantitative analysis. Association between rated scores and
each domain was explored using Students’ t-test and ANOVA at 95% confidence
interval. RESULTS: Four hundred and seven (407) patients (74males 333 females)
participated.Majority of the patients (147, 36.1%) aged 20 to 30 years and 239 (58.7%)
were notmarried. Also, 338 (83.0%) earned below$1500 pa and 303 (74.4%) had basic
education. HAT-QOL scores indicated: Overall function (89.96 5.62); Life satisfac-
tion (91.94  3.62); Health worries (87.06  4.28); Financial worries (81.00  3.95);
Medication worries (91.65  4.47); HIV mastery (71.00  3.11); Disclosure worries
(27.50 7.58); Provider trust (91.63 1.96); and Sexual function (70.25 3.52). Rated
scores were in congruence with HAT-QOL scores. Provider trust was associated
with gender, employment status, and educational level, (P 0.05). CONCLUSIONS:
Patients reported satisfactory quality of life in the various domains except disclo-
sure worries, indicating concerns for discrimination and stigmatization. Provider
trust was associated with gender, employment status, and educational level. Sex-
ual function was associated with gender and age of the patients.
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OBJECTIVES: Patient-reported outcome measures are central to the evaluation of
Health-Related Quality of Life (HRQL), medical care and treatment regimens. Such
measures depart from traditional clinical assessments as they are based on issues
known to be of primary importance to patients. The objective was to select PRO
questionnaires for a pharmaco-epidemiological, observational study conducted in
France to highlight the impact of HZ and PHN on patients’ daily life and Health
Related Quality of Life (HRQoL) over a 12-month follow up. METHODS: Specific
instruments review of existing PRO/HRQLwas performed trough Pubmed and PRO-
QOLID® databases; in order to select questionnaires able to measure the level/type
of pain and HRQL perceived by the patients. The main criteria taken into account
for the selection of PROmeasureswere the appropriateness, reliability, validity and
ability to detect change (patients’ follow-up assessments of PHN and HRQL were
performed by telephone calls). RESULTS: Among the existing questionnaires, five
measures were selected: Neuropathic Pain Diagnostic Questionnaire (DN4), Neu-
ropathic Pain Symptom Inventory (NPSI) designed to measure the quality and se-
verity of neuropathic pain, Zoster Brief Pain Inventory (ZBPI) tomeasure the impact
of pain and discomfort caused by HZ or PHN, the SF-12 Health Survey and the
Hospital Anxiety and Depression Scale (HADS). All measures were available in
French and the overall length of the interview was acceptable. The ZBPI, scores
have shown impact on general activity and sleep. The mean scores of Depression
and Anxiety were significantly higher in patients with PHN. The physical andmen-
tal component summaries of the SF-12 were lower in patient with persistent PHN
than the patients without PHN. CONCLUSIONS: Using PRO measures in observa-
tional studies is well accepted by the scientific community. However, a rigorous
methodology for the selection of PRO measure is mandatory to ensure medical
relevance and fulfillment of protocol requirements.
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OBJECTIVES: Selection of an appropriate patient-reported outcome (PRO) instru-
ment for clinical trials requires a clear understanding of the instrument’s sensitiv-
ity to an intervention’s anticipated impact. The purpose of this study was to exam-
ine the responsiveness of 2 health-related quality of life (HRQL) instruments
among HIV-infected adults: the disease-specific Medical Outcomes Study HIV
Health Survey (MOS-HIV), and a genericmeasure, the EQ-5D.METHODS:A targeted
literature search identified clinical trials administering the MOS-HIV or EQ-5D and
evaluating HIV-infected adults from 2005-2010, or earlier when fewer than 5 stud-
ies were identified. Key data abstracted from each study included study type, treat-
ment regimen(s), PRO results, and effect size (either reported or calculated). Effect
size was calculated as the difference between baseline and follow-up mean scores
divided by the baseline standard deviation and was interpreted as small (d0.20),
medium (d0.50), and large (d0.80) [Cohen 1988]. RESULTS: In the past 5 years,
the MOS-HIV was administered in 12 trials. Significant differences were observed
between groups and over time in physical health summary (PHS) and mental
health summary (MHS) scores (p0.05) in subjects switching therapy after experi-
encing adverse events (grade 2 or higher). Effect sizes were medium (0.55 and 0.49
for PHS and MHS, respectively) among treatment-naïve adults beginning therapy
(n2 studies), but negligible among treatment-experienced adults (0.04 and 0.13 for
PHS and MHS, respectively; n3 studies). The EQ-5D was administered in 5 trials
during the past 10 years. The EQ-5D was responsive to occurrences of adverse
events (n2 studies), opportunistic infections (n1 study), and demonstrated
small-to-medium effect sizes (range 0.30-0.50) in treatment-experienced patients
(n1 study). CONCLUSIONS: In-depth review of PRO study results showed that
both theMOS-HIV and EQ-5Dwere responsive to changes in HIV-infected patients.
These instruments may be used either individually or together in clinical trials to
demonstrate changes in HRQL.
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OBJECTIVES: Universal vaccination against Hepatitis B virus (HBV) is effective to
control HBV infection. Hepatitis B immunoglobulin (HBIG) given to neonates helps
further reduce HBV transmission. The objectives are 1) to compare the cost-effec-
tiveness of four strategies for HBV screening and HBIG treatment in settings with a
universal vaccination policy, and 2) to identify cost-effective HBIG strategies for
different HBV prevalence rates. METHODS: We used Taiwan as an example and
developed a decision analysis model to estimate the clinical and economic out-
comes of HBV infection for a hypothetical cohort of 100,000 newborns. The four
strategies were 1) Strategy V: vaccination only for all neonates, no screening or
HBIG treatment,; 2) Strategy S: maternal screening HBsAg, HBIG given for neonates
born to HBsAg-positive mothers; 3) Strategy E: maternal screening HBeAg, HBIG
given for neonates born to HBeAg-positive mothers; and 4) Strategy S&E: maternal
screening HBsAg then HBeAg, HBIG given for neonates born to HBeAg-positive
carrier mothers. RESULTS: In Taiwan, if willing-to-pay (WTP) over $3000 to avert a
case of HBV infection, Strategy S would provide the best protection. For WTP be-
tween $1500-3000, Strategy E would be preferred at HBV prevalence  14%, fol-
lowed by Strategy S&E at prevalence 5-13%, and finally Strategy S at prevalence 
5%. For WTP less than $1,500, Strategy V would be optimal. CONCLUSIONS: The
optimal strategy is a function of WTP and HBV prevalence which usually declines
gradually following the launch of immunization. This study provides a roadmap for
considering alternative approaches to targeting HBIG treatment after the introduc-
tion of HBV vaccine.
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